A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

Cancer biology finds itself in a post-genomic era and the hopes of using inherited genetic variants to improve prevention and treatment strategies are widespread. One of the largest types of inherited genetic variation is the single nucleotide polymorphism (SNP), of which there are at least 4.5 million. The challenge now becomes how to discover which polymorphisms alter cancer in humans and how to begin to understand their mechanism of action. In this report, a series of recent publications will be reviewed that have studied a polymorphism in the p53 tumor suppressor pathway, MDM2 SNP309. These reports have lent insights into how germline genetic variants of the p53 pathway could interact with gender, environmental stresses and tumor genetics to affect cancer in humans. Importantly, these observations have also exposed potential nodes of intervention, which could prove valuable in both the prevention and treatment of this disease in humans.

[1]  J. Kemper,et al.  Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  C. Prives,et al.  Excess HDM2 Impacts Cell Cycle and Apoptosis and Has a Selective Effect on p53-dependent Transcription* , 2006, Journal of Biological Chemistry.

[3]  N. Kato,et al.  MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006, Clinical Cancer Research.

[4]  A. Levine,et al.  A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. , 2005, Cancer research.

[5]  Brad Saville,et al.  Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor α and SP proteins , 2004, Oncogene.

[6]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[7]  S. Zienolddiny,et al.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer , 2006, International journal of cancer.

[8]  C. Osborne,et al.  Steroid hormone receptors in breast cancer management , 2004, Breast Cancer Research and Treatment.

[9]  R. Bertorelle,et al.  Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. , 2006, Journal of the National Cancer Institute.

[10]  H. Nguyen,et al.  Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  L. J. Veer,et al.  The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.

[12]  P. Bugert,et al.  The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. , 2006, Cancer research.

[13]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[14]  S. Safe,et al.  Estrogen receptor/Sp1 complexes are required for induction of cad gene expression by 17beta-estradiol in breast cancer cells. , 2003, Endocrinology.

[15]  E. Bowman,et al.  MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[16]  Y. Hirooka,et al.  MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Sandya Liyanarachchi,et al.  p53 Codon 72 and MDM2 SNP309 Polymorphisms and Age of Colorectal Cancer Onset in Lynch Syndrome , 2005, Clinical Cancer Research.

[18]  G. Tomlinson,et al.  MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia , 2005, Leukemia.

[19]  A. Levine,et al.  MDM2 SNP309 accelerates colorectal tumour formation in women , 2006, Journal of Medical Genetics.

[20]  Hiroyuki Yamamoto,et al.  Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells , 2006, Journal of Medical Genetics.

[21]  Hongbing Shen,et al.  Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. , 2006, Cancer letters.

[22]  D. Lane,et al.  Exploiting the p53 pathway for the diagnosis and therapy of human cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[23]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[24]  D. DeMarini.  Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. , 2004, Mutation research.

[25]  J. Park,et al.  MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. , 2006, Lung cancer.

[26]  D. Eccles,et al.  Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers , 2006, BMC Cancer.

[27]  J. Blaydes,et al.  p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. , 2003, Cancer research.

[28]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.

[29]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[30]  M. Spitz,et al.  MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. , 2006, Carcinogenesis.

[31]  C. Cordon-Cardo,et al.  MDM2 and prognosis. , 2004, Molecular cancer research : MCR.

[32]  B. Wasylyk,et al.  MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis , 2000, The EMBO journal.

[33]  A. Levine,et al.  A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells* , 2005, Journal of Biological Chemistry.

[34]  A. Levine,et al.  Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.

[35]  D. Eccles,et al.  No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.

[36]  L. Attardi,et al.  Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice , 2006, Cell Death and Differentiation.

[37]  G. Lozano,et al.  Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.

[38]  奥村 直樹.  Distinct promoter usage of mdm2 gene in human breast cancer , 2002 .

[39]  A. Marchetti,et al.  mdm2 gene alterations and mdm2 protein expression in breast carcinomas , 1995, The Journal of pathology.

[40]  B. Iacopetta,et al.  p53 and disease: when the guardian angel fails , 2006, Cell Death and Differentiation.

[41]  C. Bonaïti‐pellié,et al.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.

[42]  M. Levrero.  Viral hepatitis and liver cancer: the case of hepatitis C , 2006, Oncogene.

[43]  N. Kato,et al.  MDM 2 Promoter SNP 309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006 .

[44]  T. Sawada,et al.  [Estrogen receptor (ER), progesterone receptor (PR)]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[45]  L. Donehower,et al.  Overexpression of Mdm 2 in mice reveals a p 53-independent role for Mdm 2 in tumorigenesis , 1998 .

[46]  L. Aaltonen,et al.  The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.

[47]  H. Kinyamu,et al.  Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression , 2003, Molecular and Cellular Biology.

[48]  W. Tan,et al.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.

[49]  R. Millikan,et al.  No Association Between the MDM2 −309 T/G Promoter Polymorphism and Breast Cancer in African-Americans or Whites , 2006, Cancer Epidemiology Biomarkers & Prevention.

[50]  C. Prives,et al.  Unleashing the power of p53: lessons from mice and men. , 2006, Genes & development.

[51]  Dieter Niederacher,et al.  Multistep carcinogenesis of breast cancer and tumour heterogeneity , 1997, Journal of Molecular Medicine.

[52]  Hongbing Shen,et al.  Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population , 2006, International journal of cancer.

[53]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[54]  Wen Tan,et al.  Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.

[55]  T. Greiner,et al.  Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.

[56]  R. Eisenman,et al.  Tumor suppression and normal aging in mice with constitutively high p53 activity. , 2006, Genes & development.

[57]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[58]  M. Sheikh,et al.  The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. , 1993, Cancer research.